This educational newsletter is intended for hematologists, oncologists, and other healthcare professional interested in the management of patients with hematologic malignancies. The information on this site is intended for healthcare professionals based outside of the United States.

After successful completion of this educational activity, participants should be able to:

• Examine recent clinical trial data on the efficacy and safety of treatment options for chronic myeloid leukemia (CML), including integration of optimal therapies into clinical practice
• Evaluate current standards of care and recent clinical data regarding therapeutic advances in the management of patients with Phildelphia chromosome-negative myeloproliferative neoplasms (MPN) and the practical implications of these data
• Discuss recent advances in the treatment of multiple myeloma (MM), including novel therapies and emerging treatment strategies for those with relapsed and/or refractory disease
• Describe recent clinical trial data regarding the treatment of patients with myelodysplastic syndrome (MDS), including management of iron overload and the role of chelation therapy

Disclosure of Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.